Brief: Alligator Bioscience, Aptevo Therapeutics Announce Positive Interim Data From Dose Escalation Phase Of Their Phase 1 Trial
16/09/2024 13:12
Sept 16 (Reuters) - Alligator Bioscience AB ATORX.ST
* CO AND APTEVO THERAPEUTICS TODAY ANNOUNCED POSITIVE
INTERIM DATA
FROM DOSE ESCALATION PHASE OF THEIR PHASE 1 TRIAL EVALUATING
ALG.APV-527 FOR TREATMENT OF SOLID TUMORS LIKELY TO EXPRESS
TUMOR ANTIGEN 5T4
Source text for Eikon: ID:nMFN46GfS4
Further company coverage: ATORX.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com;))
Recent news on Aptevo Therapeutics
See all newsBrief: Aptevo Therapeutics - Enters Amendment No. 6 To Rights Agreement On October 23, 2026 - SEC Filing
U.S. STOCKS ON THE MOVE-Principal Financial Group, NetApp
U.S. STOCKS ON THE MOVE-Genesco, Fervo Energy, Tyson Foods
Aptevo Therapeutics reports early data for blood cancer therapy; shares fall
Aptevo Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary